PKP-008 Long term stability of trastuzumab in serum samples
BackgroundImmunoassays remain the primary analytical method for quantification of macromolecules such as monoclonal antibodies (mAbs). For the quantification of mAbs in serum or plasma, study samples are not immediately analysed once collected, and thus the various conditions that study samples unde...
Gespeichert in:
Veröffentlicht in: | European journal of hospital pharmacy. Science and practice 2016-03, Vol.23 (Suppl 1), p.A181-A182 |
---|---|
Hauptverfasser: | , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | A182 |
---|---|
container_issue | Suppl 1 |
container_start_page | A181 |
container_title | European journal of hospital pharmacy. Science and practice |
container_volume | 23 |
creator | García, J González Nicolás, F Gutiérrez Casariego, GJ Nazco Romero, MM Viña Díaz, R Ramos de la Fuente, G Sánchez, V Casañas Martínez, M Llabres |
description | BackgroundImmunoassays remain the primary analytical method for quantification of macromolecules such as monoclonal antibodies (mAbs). For the quantification of mAbs in serum or plasma, study samples are not immediately analysed once collected, and thus the various conditions that study samples undergo must be considered to ensure that analytical stability has not been compromised.PurposeTo analyse the long term stability of the monoclonal antibody trastuzumab (Herceptin) in serum samples at -20°C.Material and methodsBlood samples (1.5 mL) were stored in K2EDTA tubes (Becton Dickinson, USA). They were immediately sent to the laboratory, centrifuged (2 × 3000 g/5 min) and were divided into two aliquots. One aliquot was immediately analysed. The second aliquot was stored at −20°C for 2 months and then analysed. The immediately analysed samples were considered the baseline value. At the time of analysis, both samples were analysed at dilutions of 1/20 and 1/80 in duplicate to minimise pipetting errors and the intrinsic variation of the method. Serum trastuzumab concentrations were determined by enzyme linked immunosorbent assay (ELISA) using the automated analyser TRITURUS (Grifols). SPSS statistical (v.22.0.0.0) program was used for statistical analysis. Repeated measurements made from the same samples kept under different storage conditions were tested using the Wilcoxon test. A p value |
doi_str_mv | 10.1136/ejhpharm-2016-000875.411 |
format | Article |
fullrecord | <record><control><sourceid>proquest_bmj_p</sourceid><recordid>TN_cdi_proquest_journals_2552751958</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2552751958</sourcerecordid><originalsourceid>FETCH-LOGICAL-b1008-247a8a61a803f7c01db2d72715876bfeb0e33cf3cfc25d41f772268116261e3b3</originalsourceid><addsrcrecordid>eNp9kLtOwzAUhi0EElXpO1hiTvHxPQMDqrhUVKIDzJadODRR0wQ7GcrEwovyJLgqMCId6Zzh-_8jfQhhIHMAJq98s-k3NrQZJSAzQohWYs4BTtCEEq6yPJf89O8W8hzNYqwdEYzpnLN8gq7Xj-sU1F8fn6tu94oHH1ocB-vqbT3scVfhIdg4jO9jax2udzj6MCbCtv3Wxwt0Vtlt9LOfPUUvd7fPi4ds9XS_XNysMgepO6NcWW0lWE1YpQoCpaOlogqEVtJV3hHPWFGlKagoOVRKUSo1gKQSPHNsii6PvX3o3kYfB9N0Y9ill4YKQZWAXOj_KFCaC5FrRRPFjpRrG9OHurVhb4CYg1DzK9QchJqjUJOEsm_652k_</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1784559872</pqid></control><display><type>article</type><title>PKP-008 Long term stability of trastuzumab in serum samples</title><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><creator>García, J González ; Nicolás, F Gutiérrez ; Casariego, GJ Nazco ; Romero, MM Viña ; Díaz, R Ramos ; de la Fuente, G ; Sánchez, V Casañas ; Martínez, M Llabres</creator><creatorcontrib>García, J González ; Nicolás, F Gutiérrez ; Casariego, GJ Nazco ; Romero, MM Viña ; Díaz, R Ramos ; de la Fuente, G ; Sánchez, V Casañas ; Martínez, M Llabres</creatorcontrib><description>BackgroundImmunoassays remain the primary analytical method for quantification of macromolecules such as monoclonal antibodies (mAbs). For the quantification of mAbs in serum or plasma, study samples are not immediately analysed once collected, and thus the various conditions that study samples undergo must be considered to ensure that analytical stability has not been compromised.PurposeTo analyse the long term stability of the monoclonal antibody trastuzumab (Herceptin) in serum samples at -20°C.Material and methodsBlood samples (1.5 mL) were stored in K2EDTA tubes (Becton Dickinson, USA). They were immediately sent to the laboratory, centrifuged (2 × 3000 g/5 min) and were divided into two aliquots. One aliquot was immediately analysed. The second aliquot was stored at −20°C for 2 months and then analysed. The immediately analysed samples were considered the baseline value. At the time of analysis, both samples were analysed at dilutions of 1/20 and 1/80 in duplicate to minimise pipetting errors and the intrinsic variation of the method. Serum trastuzumab concentrations were determined by enzyme linked immunosorbent assay (ELISA) using the automated analyser TRITURUS (Grifols). SPSS statistical (v.22.0.0.0) program was used for statistical analysis. Repeated measurements made from the same samples kept under different storage conditions were tested using the Wilcoxon test. A p value <0.05 was considered to be significant. The research protocol was approved by the local ethics committee of our institution.ResultsBlood samples from 4 patients a with diagnosis of HER2+ breast cancer receiving treatment with subcutaneus trastuzumab (Herceptin) were included in the study after providing written informed consent. We did not find a significant difference between the samples analysed immediately and those stored at -20°C for 60 days (p = 0.414) (table 1).Abstract PKP-008 Table 1PatientTrastuzumab concentration day 1 (μg/mL)Trastuzumab concentration day 60 (μg/mL)Difference (%)146484.327068-2.835050048682-4.65ConclusionIn our study, we observed that serum trastuzumab (Herceptin) samples stored at -20°C were stable for at least 2 months. This was consistent with previous studies.References and/or AcknowledgementsFicha Técnica HerceptinNo conflict of interest.</description><identifier>ISSN: 2047-9956</identifier><identifier>EISSN: 2047-9964</identifier><identifier>DOI: 10.1136/ejhpharm-2016-000875.411</identifier><language>eng</language><publisher>London: BMJ Publishing Group LTD</publisher><subject>Breast cancer</subject><ispartof>European journal of hospital pharmacy. Science and practice, 2016-03, Vol.23 (Suppl 1), p.A181-A182</ispartof><rights>2016, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions</rights><rights>Copyright: 2016 (c) 2016, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions</rights><rights>2016 2016, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids></links><search><creatorcontrib>García, J González</creatorcontrib><creatorcontrib>Nicolás, F Gutiérrez</creatorcontrib><creatorcontrib>Casariego, GJ Nazco</creatorcontrib><creatorcontrib>Romero, MM Viña</creatorcontrib><creatorcontrib>Díaz, R Ramos</creatorcontrib><creatorcontrib>de la Fuente, G</creatorcontrib><creatorcontrib>Sánchez, V Casañas</creatorcontrib><creatorcontrib>Martínez, M Llabres</creatorcontrib><title>PKP-008 Long term stability of trastuzumab in serum samples</title><title>European journal of hospital pharmacy. Science and practice</title><description>BackgroundImmunoassays remain the primary analytical method for quantification of macromolecules such as monoclonal antibodies (mAbs). For the quantification of mAbs in serum or plasma, study samples are not immediately analysed once collected, and thus the various conditions that study samples undergo must be considered to ensure that analytical stability has not been compromised.PurposeTo analyse the long term stability of the monoclonal antibody trastuzumab (Herceptin) in serum samples at -20°C.Material and methodsBlood samples (1.5 mL) were stored in K2EDTA tubes (Becton Dickinson, USA). They were immediately sent to the laboratory, centrifuged (2 × 3000 g/5 min) and were divided into two aliquots. One aliquot was immediately analysed. The second aliquot was stored at −20°C for 2 months and then analysed. The immediately analysed samples were considered the baseline value. At the time of analysis, both samples were analysed at dilutions of 1/20 and 1/80 in duplicate to minimise pipetting errors and the intrinsic variation of the method. Serum trastuzumab concentrations were determined by enzyme linked immunosorbent assay (ELISA) using the automated analyser TRITURUS (Grifols). SPSS statistical (v.22.0.0.0) program was used for statistical analysis. Repeated measurements made from the same samples kept under different storage conditions were tested using the Wilcoxon test. A p value <0.05 was considered to be significant. The research protocol was approved by the local ethics committee of our institution.ResultsBlood samples from 4 patients a with diagnosis of HER2+ breast cancer receiving treatment with subcutaneus trastuzumab (Herceptin) were included in the study after providing written informed consent. We did not find a significant difference between the samples analysed immediately and those stored at -20°C for 60 days (p = 0.414) (table 1).Abstract PKP-008 Table 1PatientTrastuzumab concentration day 1 (μg/mL)Trastuzumab concentration day 60 (μg/mL)Difference (%)146484.327068-2.835050048682-4.65ConclusionIn our study, we observed that serum trastuzumab (Herceptin) samples stored at -20°C were stable for at least 2 months. This was consistent with previous studies.References and/or AcknowledgementsFicha Técnica HerceptinNo conflict of interest.</description><subject>Breast cancer</subject><issn>2047-9956</issn><issn>2047-9964</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNp9kLtOwzAUhi0EElXpO1hiTvHxPQMDqrhUVKIDzJadODRR0wQ7GcrEwovyJLgqMCId6Zzh-_8jfQhhIHMAJq98s-k3NrQZJSAzQohWYs4BTtCEEq6yPJf89O8W8hzNYqwdEYzpnLN8gq7Xj-sU1F8fn6tu94oHH1ocB-vqbT3scVfhIdg4jO9jax2udzj6MCbCtv3Wxwt0Vtlt9LOfPUUvd7fPi4ds9XS_XNysMgepO6NcWW0lWE1YpQoCpaOlogqEVtJV3hHPWFGlKagoOVRKUSo1gKQSPHNsii6PvX3o3kYfB9N0Y9ill4YKQZWAXOj_KFCaC5FrRRPFjpRrG9OHurVhb4CYg1DzK9QchJqjUJOEsm_652k_</recordid><startdate>201603</startdate><enddate>201603</enddate><creator>García, J González</creator><creator>Nicolás, F Gutiérrez</creator><creator>Casariego, GJ Nazco</creator><creator>Romero, MM Viña</creator><creator>Díaz, R Ramos</creator><creator>de la Fuente, G</creator><creator>Sánchez, V Casañas</creator><creator>Martínez, M Llabres</creator><general>BMJ Publishing Group LTD</general><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>BTHHO</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope></search><sort><creationdate>201603</creationdate><title>PKP-008 Long term stability of trastuzumab in serum samples</title><author>García, J González ; Nicolás, F Gutiérrez ; Casariego, GJ Nazco ; Romero, MM Viña ; Díaz, R Ramos ; de la Fuente, G ; Sánchez, V Casañas ; Martínez, M Llabres</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-b1008-247a8a61a803f7c01db2d72715876bfeb0e33cf3cfc25d41f772268116261e3b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Breast cancer</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>García, J González</creatorcontrib><creatorcontrib>Nicolás, F Gutiérrez</creatorcontrib><creatorcontrib>Casariego, GJ Nazco</creatorcontrib><creatorcontrib>Romero, MM Viña</creatorcontrib><creatorcontrib>Díaz, R Ramos</creatorcontrib><creatorcontrib>de la Fuente, G</creatorcontrib><creatorcontrib>Sánchez, V Casañas</creatorcontrib><creatorcontrib>Martínez, M Llabres</creatorcontrib><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>BMJ Journals</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><jtitle>European journal of hospital pharmacy. Science and practice</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>García, J González</au><au>Nicolás, F Gutiérrez</au><au>Casariego, GJ Nazco</au><au>Romero, MM Viña</au><au>Díaz, R Ramos</au><au>de la Fuente, G</au><au>Sánchez, V Casañas</au><au>Martínez, M Llabres</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>PKP-008 Long term stability of trastuzumab in serum samples</atitle><jtitle>European journal of hospital pharmacy. Science and practice</jtitle><date>2016-03</date><risdate>2016</risdate><volume>23</volume><issue>Suppl 1</issue><spage>A181</spage><epage>A182</epage><pages>A181-A182</pages><issn>2047-9956</issn><eissn>2047-9964</eissn><abstract>BackgroundImmunoassays remain the primary analytical method for quantification of macromolecules such as monoclonal antibodies (mAbs). For the quantification of mAbs in serum or plasma, study samples are not immediately analysed once collected, and thus the various conditions that study samples undergo must be considered to ensure that analytical stability has not been compromised.PurposeTo analyse the long term stability of the monoclonal antibody trastuzumab (Herceptin) in serum samples at -20°C.Material and methodsBlood samples (1.5 mL) were stored in K2EDTA tubes (Becton Dickinson, USA). They were immediately sent to the laboratory, centrifuged (2 × 3000 g/5 min) and were divided into two aliquots. One aliquot was immediately analysed. The second aliquot was stored at −20°C for 2 months and then analysed. The immediately analysed samples were considered the baseline value. At the time of analysis, both samples were analysed at dilutions of 1/20 and 1/80 in duplicate to minimise pipetting errors and the intrinsic variation of the method. Serum trastuzumab concentrations were determined by enzyme linked immunosorbent assay (ELISA) using the automated analyser TRITURUS (Grifols). SPSS statistical (v.22.0.0.0) program was used for statistical analysis. Repeated measurements made from the same samples kept under different storage conditions were tested using the Wilcoxon test. A p value <0.05 was considered to be significant. The research protocol was approved by the local ethics committee of our institution.ResultsBlood samples from 4 patients a with diagnosis of HER2+ breast cancer receiving treatment with subcutaneus trastuzumab (Herceptin) were included in the study after providing written informed consent. We did not find a significant difference between the samples analysed immediately and those stored at -20°C for 60 days (p = 0.414) (table 1).Abstract PKP-008 Table 1PatientTrastuzumab concentration day 1 (μg/mL)Trastuzumab concentration day 60 (μg/mL)Difference (%)146484.327068-2.835050048682-4.65ConclusionIn our study, we observed that serum trastuzumab (Herceptin) samples stored at -20°C were stable for at least 2 months. This was consistent with previous studies.References and/or AcknowledgementsFicha Técnica HerceptinNo conflict of interest.</abstract><cop>London</cop><pub>BMJ Publishing Group LTD</pub><doi>10.1136/ejhpharm-2016-000875.411</doi></addata></record> |
fulltext | fulltext |
identifier | ISSN: 2047-9956 |
ispartof | European journal of hospital pharmacy. Science and practice, 2016-03, Vol.23 (Suppl 1), p.A181-A182 |
issn | 2047-9956 2047-9964 |
language | eng |
recordid | cdi_proquest_journals_2552751958 |
source | Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central |
subjects | Breast cancer |
title | PKP-008 Long term stability of trastuzumab in serum samples |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-05T20%3A46%3A35IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_bmj_p&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=PKP-008%E2%80%85Long%20term%20stability%20of%20trastuzumab%20in%20serum%20samples&rft.jtitle=European%20journal%20of%20hospital%20pharmacy.%20Science%20and%20practice&rft.au=Garc%C3%ADa,%20J%20Gonz%C3%A1lez&rft.date=2016-03&rft.volume=23&rft.issue=Suppl%201&rft.spage=A181&rft.epage=A182&rft.pages=A181-A182&rft.issn=2047-9956&rft.eissn=2047-9964&rft_id=info:doi/10.1136/ejhpharm-2016-000875.411&rft_dat=%3Cproquest_bmj_p%3E2552751958%3C/proquest_bmj_p%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1784559872&rft_id=info:pmid/&rfr_iscdi=true |